<u>'able of Contents</u> JUPPLEMENTARY TEXT
Supplementary Methods: Change and Substitution Models Included in the Meta-Analysis.
SUPPLEMENTARY TABLES
Supplementary Table 1. Search strategy for low-and no-calorie sweetened beverages (LNCSBs).
Supplementary Table 2. Search strategy for water.
Supplementary Table 3. Pre-specified Confounding Variables for Examined Outcomes
Supplementary Table 4A. Analysis of confounding variables among prospective cohorts using change analysis o LNCSBs on cardiometabolic outcomes
Supplementary Table 4B. Analysis of confounding variables among prospective cohorts using substitution analysis of LNCSBs on cardiometabolic outcomes1
Supplementary Table 5A. Newcastle-Ottawa Scale (NOS) for assessing the quality of cohort comparisons using change analysis presented by cohort comparisons
Supplementary Table 5B. Newcastle-Ottawa Scale (NOS) for assessing the quality of cohorts using substitution analysis presented by cohort comparisons
Supplementary Table 6A. Grading of Recommendations Assessment, Development, and Evaluation (GRADE) Assessment for Outcomes using change analysis1
Supplementary Table 6B. Grading of Recommendations Assessment, Development, and Evaluation (GRADE) Assessment for Outcomes using substitution analysis
Supplementary Table 6C. NutriGRADE Assessment for Outcomes using change analysis2
Supplementary Table 6D. NutriGRADE Assessment for Outcomes using substitution analysis
Supplementary Table 7. Minimum Important Difference (MID) used for the imprecision in GRADE assessments
SUPPLEMENTARY FIGURES
Supplementary Figure 1. Consort diagram outlining the summary of evidence search and selection for water substitution and cardiometabolic outcomes
Supplementary Figure 2A. Relationship between increasing one serving (330 mL) of low-and no-calorie sweetened beverage (LNCSB) intake a day and change in body weight (kg) per year using a fixed-effects model.
Supplementary Figure 2B. Relationship between increasing one serving (330 mL) of low-and no-calorie sweetened beverage (LNCSB) intake a day and change in waist circumference (cm) per year using a fixed-effect model
Supplementary Figure 2C. Relationship between increasing one serving (330 mL) of low-and no-calorie sweetened beverage (LNCSB) intake a day and type 2 diabetes (T2D) incidence using a fixed-effects model2
Supplementary Figure 3A. Relationship between substituting low-and no-calorie sweetened beverages (LNCSBs for sugar-sweetened beverages (SSBs) and change in body weight (kg) per year using a fixed-effects model2

Supplementary Figure 3B. Relationship between substituting low-and no-calorie sweetened beverages (LNCSBs) for sugar-sweetened beverages (SSBs) and change in waist circumference (cm) per year
Supplementary Figure 3C. Relationship between substituting low-and no-calorie sweetened beverages (LNCSBs) for sugar-sweetened beverages (SSBs) and change in percent body fat (%) per year
Supplementary Figure 3D. Relationship between substituting low-and no-calorie sweetened beverages (LNCSBs) for sugar-sweetened beverages (SSBs) and obesity (OB) incidence
Supplementary Figure 3E. Relationship between substituting low-and no-calorie sweetened beverages (LNCSBs) for sugar-sweetened beverages (SSBs) and type 2 diabetes (T2D) incidence using a fixed-effects model
Supplementary Figure 3F. Relationship between substituting low-and no-calorie sweetened beverages (LNCSBs) for sugar-sweetened beverages (SSBs) and coronary heart disease (CHD) incidence using DerSimonian-Laird random-effects model
Supplementary Figure 3G. Relationship between substituting low-and no-calorie sweetened beverages (LNCSBs) for sugar-sweetened beverages (SSBs) and stroke incidence
Supplementary Figure 3H. Relationship between substituting low-and no-calorie sweetened beverages (LNCSBs) for sugar-sweetened beverages (SSBs) and the risk of coronary heart disease (CHD) mortality using a fixed-effects model
Supplementary Figure 3I. Relationship between substituting low-and no-calorie sweetened beverages (LNCSBs) for sugar-sweetened beverages (SSBs) and the risk of total cardiovascular disease (CVD) mortality
Supplementary Figure 3J. Relationship between substituting low-and no-calorie sweetened beverages (LNCSBs) for sugar-sweetened beverages (SSBs) and the risk of total mortality
Supplementary Figure 4A. Relationship between substituting water for sugar-sweetened beverages (SSBs) and change in body weight (kg) per year using a fixed-effects model
Supplementary Figure 4B. Relationship between substituting water for sugar-sweetened beverages (SSBs) and change in waist circumference (cm) per year
Supplementary Figure 4C. Relationship between substituting water for sugar-sweetened beverages (SSBs) and change in percent body fat (%) per year
Supplementary Figure 4D. Relationship between substituting water for sugar-sweetened beverages (SSBs) and obesity (OB) incidence
Supplementary Figure 4E. Relationship between substituting water for sugar-sweetened beverages and the risk of type 2 diabetes (T2D) using a fixed-effects model
Supplementary Figure 4F. Relationship between substituting water for sugar-sweetened beverages (SSBs) and stroke incidence
Supplementary Figure 5A. Relationship between substituting low-and no-calorie sweetened beverages (LNCSBs) for water and change in body weight (kg) per year
Supplementary Figure 5B. Relationship between substituting low-and no-calorie sweetened beverages (LNCSBs) for water and obesity (OB) incidence
Supplementary Figure 5C. Relationship between substituting low-and no-calorie sweetened beverages (LNCSBs) for water and the risk of type 2 diabetes (T2D) using a fixed-effects model

Supplementary Figure 5D. Relationship between substituting low-and no-calorie sweetened beverages for water and stroke incidence.	(LNCSBs) 48
Supplementary Figure 6A. Sensitivity analysis of relationship between change in low-and no-calorie sy beverage (LNCSB) intake on change in body weight (kg) per year	weetened 49
Supplementary Figure 6B. Sensitivity analysis of relationship between change in low-and no-calorie sy beverage (LNCSB) intake on risk of type 2 diabetes (T2D)	<i>w</i> eetened 50
Supplementary Figure 7A. Sensitivity analysis of relationship between substituting low-and no-calorie beverages (LNCSBs) for sugar-sweetened beverages (SSBs) on change in body weight (kg) per year	sweetened
Supplementary Figure 7B. Sensitivity analysis of relationship between substituting low-and no-calorie beverages (LNCSBs) for sugar-sweetened beverages (SSBs) and risk of type 2 diabetes (T2D)	sweetened52
Supplementary Figure 7C. Sensitivity analysis of relationship between substituting low-and no-calorie beverages (LNCSBs) for sugar-sweetened beverages (SSBs) and coronary heart disease (CHD) incider	sweetened nce53
Supplementary Figure 7D. Sensitivity analysis of relationship between substituting low-and no-calorie beverages (LNCSBs) for sugar-sweetened beverages (SSBs) and risk of coronary heart disease (CHD)	sweetened mortality. 54
Supplementary Figure 8A. Sensitivity analysis of relationship between substituting water for sugar-swe beverages (SSBs) on change in body weight (kg) per year.	eetened 55
Supplementary Figure 8B. Sensitivity analysis of relationship between substituting water for sugar-swee beverages (SSBs) and risk of type 2 diabetes (T2D).	eetened 56
Supplementary Figure 9. Sensitivity analysis of relationship between substituting low-and no-calorie substituting (LNCSBs) for water and risk of type 2 diabetes (T2D)	weetened 57
Supplementary Figure 10. Linear and non-linear dose-response relation between increasing low-and no sweetened beverage (LNCSB) intake and risk of type of 2 diabetes (T2D)	>-calorie 58
REFERENCES	9

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

SUPPLEMENTARY TEXT.

Supplementary Methods: Change and Substitution Models Included in the Meta-Analysis.

The change analysis mimicked a quasi-experimental study design to assess the association of the change in low-and no-calorie sweetened beverage (LNCSBs) intake with the concurrent change in outcome during the same time-period. We used the concurrent-change analysis because it shows more robust, consistent, and biologically plausible results in prospective cohort studies compared with the lagged-change analysis(1; 2). The substitution analysis examined the intended use of LNCSBs by assessing the association of substituting LNCSBs for another beverage with the change in outcome. A statistical model was used to estimate the outcome with increasing LNCSB intake while simultaneously decreasing the intake of sugar sweetened beverages (SSBs) or water, matched by beverage volume (1 mL: 1 mL). SSBs were selected as the intended substitution of LNCSBs without caloric displacement; therefore, it acted as the 'reference substitution' to SSBs ('intended substitution').

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

SUPPLEMENTARY TABLES

Supplementary Table 1. Search strategy for low-and no-calorie sweetened beverages (LNCSBs).

MEDL	INE	EMB	ASE	Cochrane					
1	artifi* sweet*.mp.	1	artifi* sweet*.mp.	1	artifi* sweet*.mp.				
2	non-calori*.mp.	2	non-calori*.mp.	2	non-calori*.mp.				
3	noncalori*.mp.	3	noncalori*.mp.	3	noncalori*.mp.				
4	non-caloric.mp.	4	non-caloric.mp.	4	non-caloric.mp.				
5	non-sugar.mp.	5	non-sugar.mp.	5	non-sugar.mp.				
6	nonsugar.mp.	6	nonsugar.mp.	6	nonsugar.mp.				
7	non-nutritive*.mp.	7	non-nutritive*.mp.	7	non-nutritive*.mp.				
8	nonnutritive*.mp.	8	nonnutritive*.mp.	8	nonnutritive*.mp.				
9	low-calori*.mp.	9	low-calori*.mp.	9	low-calori*.mp.				
10	lowcalori*.mp.	10	lowcalori*.mp.	10	lowcalori*.mp.				
11	natural sweet*.mp.	11	natural sweet*.mp.	11	natural sweet*.mp.				
12	natural sweetening agent*.mp.	12	natural sweetening agent*.mp.	12	natural sweetening agent*.mp.				
13	non-nutritive sweetener/	13	non-nutritive sweetener/	13	non-nutritive sweetener/				
14	sweetening agent*.mp.	14	sweetening agent*.mp.	14	sweetening agent*.mp.				
15	sugar substitute*.mp.	15	sugar substitute*.mp.	15	sugar substitute*.mp.				
16	zero calori*.mp.	16	zero calori*.mp.	16	zero calori*.mp.				
17	no calori*.mp.	17	no calori*.mp.	17	no calori*.mp.				
18	sugar-free.mp.	18	sugar-free.mp.	18	sugar-free.mp.				
19	diet beverage.mp.	19	diet beverage.mp.	19	diet beverage.mp.				
20	artificial* sweet* beverage.mp.	20	artificial* sweet* beverage.mp.	20	artificial* sweet* beverage.mp.				
21	cohort study.mp.	21	cohort study.mp.	21	cohort study.mp.				
22	prospective cohort.mp.	22	prospective cohort.mp.	22	prospective cohort.mp.				
23	relative risk:.tw.	23	relative risk:.tw.	23	relative risk:.tw.				
24	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20	24	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20	24	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20				
25	21 or 22 or 23	25	21 or 22 or 23	25	21 or 22 or 23				
26	24 and 25	26	24 and 25	26	24 and 25				
27	limit 26 to animals	27	limit 26 to animals						
28	26 not 27	28	26 not 27						

Database	Total
MEDLINE: June 10, 2021	191
EMBASE: June 10, 2021	235
Cochrane: May, 2021	165
Manual search	85
Total	676
Duplicates	190
Final Total	486

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

Supplementary Table 2. Search strategy for water.

To identify studies that examine the substitution of water for sugar-sweetened beverages (SSBs) and cardiometabolic health, an additional search was conducted.

MEDLINE		EMBA	ASE	Cochrane					
1	water*.mp.	1	water*.mp.	1	water*.mp.				
2	substitut*.mp.	2	substitut*.mp.	2	substitut*.mp.				
3	replac*.mp.	3	replac*.mp.	3	replac*.mp.				
4	cohort study.mp.	4	cohort study.mp.	4	cohort study.mp.				
5	prospective cohort.mp.	5	prospective cohort.mp.	5	prospective cohort.mp.				
6	relative risk:.tw.	6	relative risk:.tw.	6	relative risk:.tw.				
7	2 or 3	7	2 or 3	7	2 or 3				
8	4 or 5 or 6	8	4 or 5 or 6	8	4 or 5 or 6				
9	1 and 7 and 8	9	1 and 7 and 8	9	1 and 7 and 8				
10	Limit 9 to animals	10	Limit 9 to animals	10					
11	9 not 10	11	9 not 10	11					

Database	Total
<u>MEDLINE:</u> June 10, 2021	95
<u>EMBASE:</u> June 10, 2021	80
Cochrane: May, 2021	18
Manual search	5
Total	198
Duplicates	55
Final Total	143

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

		Measured Outcome(s)	
	Adiposity Measures & Metabolic Syndrome Incidence (5/6 [†])	T2D Incidence (4/6 [†])	CVD Incidence & Total Mortality (5/7 [†])
Primary			
Confounding Variable	Age	Age	Age
	Sex	Sex	Sex
	Markers of adiposity*	Markers of adiposity [*]	Markers of adiposity [*]
Casar dama	Smoking	Smoking	Smoking
Secondary Confounding	Energy intake	Energy intake	Energy intake
Variables	Family history of metabolic syndrome	Family history of T2D	Family history of CVD
	Physical activity	Physical activity	Physical activity
			Alcohol intake

Supplementary Table 3. Pre-specified Confounding Variables for Examined Outcomes.

Abbreviations: CVD, cardiovascular disease; T2D, type 2 diabetes

*Markers of adiposity included baseline body weight, body mass index (BMI), waist circumference, or percent body fat (%BF), or change in body weight in the last 5 y prior to baseline data collection.

[†]Indicates a minimum number of pre-specified secondary confounding variables needed for one Newcastle-Ottawa Scale point for the comparability of studies.

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and metaanalysis of prospective cohort studies

Supplementary Table 4A. Analysis of confounding variables among prospective cohorts using change analysis of LNCSBs on cardiometabolic outcomes

Cohort Name (First Author, Year)	HPFS (Drouin-Chartier, 2019 (4))	HPFS (Mozzafarian, 2011 (1))	HPFS (Pan, 2013 (5))	HPFS (Smith, 2015 (2))	NHS (Drouin-Chartier, 2019 (4))	NHS (Mozzafārian, 2011 (1))	NHS (Pan, 2013 (5))	NHS (Smith, 2015 (2))	NHS II (Drouin-Chartier, 2019 (4))	NHS II (Mozzafarian, 2011 (1))	NHS II (Pan, 2013 (5))	NHS II (Smith, 2015 (2))	Mexican Teachers' Cohort (Stern, 2017 (6))	Premier (Chen, 2009 (7))
Number of variables adjusted for in the included model	18	24	27	24	19	24	27	24	20	24	27	24	20	12
PRESPECIFIED VARIABLES														
Age	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark
Sex	\checkmark^{\dagger}	\checkmark^{\dagger}	\checkmark^{\dagger}	\checkmark^{\dagger}	\checkmark^{\dagger}	\checkmark^{\dagger}	\checkmark^{\dagger}	\checkmark^{\dagger}	\checkmark^{\dagger}	\checkmark^{\dagger}	\checkmark^{\dagger}	\checkmark^{\dagger}	\checkmark^{\dagger}	\checkmark
Markers of adiposity*	\checkmark	\checkmark	√	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	√§	\checkmark
Smoking	\checkmark^{\ddagger}	√	√	\checkmark	\checkmark^{\ddagger}	\checkmark	\checkmark	\checkmark	√‡	\checkmark	\checkmark	√	√‡	
Energy intake	\checkmark				\checkmark				\checkmark					\checkmark
Family history	\checkmark				\checkmark				\checkmark					
Physical activity	√‡	√‡	√‡	√‡	√‡	↓‡	√*	√‡	√‡	√‡	√‡	√‡	√	\checkmark
OTHER CONFOUNDING VARIABLES														
Ethnicity or race	\checkmark				\checkmark				\checkmark					\checkmark
State													√	
Education														\checkmark
Physical exam	\checkmark				√				\checkmark					
Marital status														\checkmark
Employment status					1				1					√
Income														√
Intervention group					1				1					√
TV watching		√	√	√		√	√	√		√	√	√		
Sleep duration		√	√	√	1	√	√	√	1	√	√	√		
Fitness level														√‡
Menopausal status & post-menopausal hormonal therapy use					✓				~				✓	
Oral contraceptive use									\checkmark				\checkmark	
Calendar time	√				√				✓					
DIETARY INTAKE		1	1	1	1	1	1		1	1	1	1	1	1
AHEI	‡				‡				√‡					
Alcohol intake	√‡	\checkmark	√	\checkmark	√‡	√	\checkmark	\checkmark	√‡	\checkmark	\checkmark	\checkmark	√‡	
LNCSBs	1				1				\checkmark					
SSBs		√	√	\checkmark		√	\checkmark	\checkmark		\checkmark	√	√		
Fruit juice		√	√	√		√	√	1		√	√	√		
Orange or grapefruit juice													‡	
Homemade sweetened beverages													‡	
Total sugary beverages	\checkmark^{\ddagger}				√‡				√‡					

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and metaanalysis of prospective cohort studies

Coffee	√‡		√		√‡		√ √		√‡		\checkmark			1
Tea	√‡		\checkmark		√‡		\checkmark		√‡		\checkmark			
Water	√‡		√		√‡	1	√		√‡		√			
Dairy										√			√ (c)	
Milk	√‡				√‡				√‡					
Whole-fat milk			\checkmark				\checkmark				\checkmark			
Low-fat milk			√				√				√		1	
Whole-fat dairy products (Butter, cheese, and whole-fat milk)		√		~		~		~		~		~		
Low-fat dairy products (Low-fat or skim milk, and yogurt)		√		√		~		√		√		√		
Yogurt													√‡	
Fruits		√	√	√		√	√	√		√	√	√	√‡	
Vegetables		√	\checkmark	\checkmark		\checkmark	\checkmark	\checkmark		\checkmark	\checkmark	\checkmark	√‡	
Potatoes (French fries; and boiled, baked, or mashed)		√	√	√		~	√	√		√	√	√		
Whole grains		√	\checkmark	\checkmark		\checkmark	\checkmark	\checkmark		\checkmark	\checkmark	\checkmark		
Refined grains		√	\checkmark	\checkmark		\checkmark	√	\checkmark		√	\checkmark	√		
White bread													√*	
Corn tortillas													√‡	
Flour tortillas													√‡	
Red meats													√‡	
Unprocessed red meats		\checkmark	\checkmark	\checkmark		\checkmark	\checkmark	\checkmark		\checkmark	\checkmark	\checkmark		
Processed meats		\checkmark	\checkmark	\checkmark		\checkmark	\checkmark	\checkmark		\checkmark	\checkmark	\checkmark		
Sweets and desserts		√	\checkmark	\checkmark		\checkmark	\checkmark	\checkmark		\checkmark	\checkmark	\checkmark		
Potato chips		√	\checkmark	\checkmark		\checkmark	\checkmark	\checkmark		\checkmark	\checkmark	\checkmark		
Nuts		\checkmark	\checkmark	\checkmark		\checkmark	\checkmark	\checkmark		\checkmark	\checkmark	\checkmark	√‡	
Fried foods (consumed at home and away from home)		\checkmark	\checkmark	\checkmark		\checkmark	\checkmark	\checkmark		\checkmark	\checkmark	\checkmark		
Trans fat		1	\checkmark	\checkmark		\checkmark	\checkmark	\checkmark		\checkmark	\checkmark	\checkmark		

Abbreviations: AHEI, Alternate Healthy Eating Index; Health Professionals Follow-Up Study; LNCSBs, low-and no-calorie sweetened beverages; NHS, Nurses' Health Study; SSBs, Sugar-sweetened beverages

*Markers of obesity included baseline body mass index (BMI).

 \checkmark indicates variables adjusted for in the included model of primary study outcomes in the original article.

 $\sqrt{1}$ indicates variables adjusted due to the nature of the cohort (i.e., single-sex cohort).

 $\sqrt{1}$ indicates variables that measured baseline and change from baseline values.

 $\sqrt{9}$ indicates variables adjusted for during additional data analysis conducted by the authors upon request.

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and metaanalysis of prospective cohort studies

Supplementary Table 4B. Analysis of confounding variables among prospective cohorts using substitution analysis of LNCSBs on cardiometabolic outcomes.

Cohort Name (Frist Author, year)	A to Z (Stookey, 2008 (8))	ARIC - Females (Keller, 2020 (9))	ARIC - Males (Keller, 2020 (9))	ATBC (Keller, 2020 (9))	EPIC-Norfolk (O' Connor, 2015 (10))	HPFS (Drouin-Chartier, 2019 (4))	HPFS (Keller, 2020 (9))	HPFS & NHS (Bernstein, 2012 (11))	HPFS & NHS (Malik, 2019 (12))	HPFS , NHS, NHS II (Pan, 2013 (5))	IWHS (Keller, 2020 (9))	NHS (Drouin-Chartier, 2019 (4))	NHS80 (Keller, 2020 (9))	NHS86 (Keller, 2020 (9))	NHS II (Drouin-Chartier, 2019 (4))	NHS II (Pan, 2012 (13))	SUN (Frésan, 2016 (14))	WHI (Huang, 2017 (15))	WHS (Keller, 2020 (9))
Number of variables adjusted for in the included model	10	11	11	11	15	18	11	23	14	27	11	19	11	11	20	11	18	22	11
PRESPECIFIED CONFOUNDING VARL	ABLES																		
Age	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark
Sex	√§	\checkmark	\checkmark	√§	\checkmark	√§	√§	√§	√§	√§	√§	√§	√§	√§	√§	√§	\checkmark	√§	√§
Markers of adiposity*	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark
Smoking		\checkmark	\checkmark	\checkmark	\checkmark	√¶	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	√¶	\checkmark	\checkmark	√¶	\checkmark	\checkmark	\checkmark	\checkmark
Energy intake	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark		\checkmark	\checkmark	\checkmark	\checkmark	\checkmark				\checkmark
Family history					\checkmark	\checkmark		\checkmark	\checkmark			\checkmark			\checkmark	\checkmark	\checkmark	\checkmark	
Physical activity [†]	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	√1	\checkmark	\checkmark	\checkmark	√1	\checkmark	√1	\checkmark	\checkmark	√1	\checkmark	\checkmark	\checkmark	\checkmark
Alcohol intake [‡]		\checkmark	\checkmark	\checkmark	\checkmark	√1	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	√1	\checkmark	\checkmark	√1	\checkmark		\checkmark	\checkmark
OTHER CONFOUNDING VARIABLES																			
Age ²																	\checkmark		
Ethnicity or Race	\checkmark					\checkmark			\checkmark			\checkmark			\checkmark	\checkmark		\checkmark	Ì
Marital status																		\checkmark	
Education		\checkmark	\checkmark	\checkmark	\checkmark		\checkmark				\checkmark		\checkmark	\checkmark				\checkmark	\checkmark
Income																		\checkmark	
Insurance																		\checkmark	
Physical exam						\checkmark						\checkmark			\checkmark				
Occupational social class					\checkmark														
Intervention group	\checkmark									\checkmark									
TV watching										\checkmark									
Sleep duration																			
Sitting time																		\checkmark	1
Calendar time						\checkmark		\checkmark				\checkmark			\checkmark				1
Menopausal status & post-menopausal hormone therapy use								\checkmark^{\parallel}	\checkmark			\checkmark			\checkmark	\checkmark		\checkmark	
Oral contraceptive use	\checkmark														\checkmark	\checkmark			
DISEASE HISOTRY & MEDICAITONS																			
History of HTN or hypercholesterolemia									\checkmark										
History of OB																	\checkmark		
History of hysterectomy																		\checkmark	
Aspirin or other antihypertensive medications use								\checkmark	\checkmark									\checkmark	
Antihyperlipidemic medications use																		\checkmark	

		1	1	1													r	
Systolic blood pressure																	\checkmark	
DIETARY INTAKE	r		 										r	r —	r	r		-
Season of dietary intake data				\checkmark														
Vitamin E use							\checkmark											
Years of multivitamin use							\checkmark	\checkmark										
AHEI					√1			√1			√1			√1	\checkmark		\checkmark	
Energy calibration																	\checkmark	
Mediterranean diet adherence																\checkmark		
Special diet (unspecified)																\checkmark		
Snacking between meals																\checkmark		
Macronutrient intake	\checkmark																	
Energy intake from beverages																		
LNCSBs					\checkmark						\checkmark			\checkmark		\checkmark		
SSBs				\checkmark						\checkmark						\checkmark		
Fruit juice				\checkmark						\checkmark						\checkmark		
Total sugary beverages					√1						<u>ر</u> ۱			_ √ 1		-		
Coffee					√1					1	<u>_</u> 1			1		1		
Теа					./1						./1			./1		•		
Sweetened tea or coffee				./	v					v	, v			× ·		./		
Water	./			v	./1					./	./1			./1		./	-	
Dairy	v				V					v	V ·			V -		V (
Milk					1						/1			/1		v		
Whole fot wills					V "					1	V '			V '				
Whole-fat milk										V (
Low-fat milk Whole fot dainy products (Putter chases										~								
and whole-fat milk)							\checkmark											
Low-fat dairy products (Low-fat		1	1				<i>,</i>											
or skim milk, and yogurt)							\checkmark											
Sweetened-milk beverage				\checkmark														
Other dairy products										\checkmark								
Fruits							\checkmark			\checkmark								
Vegetables							\checkmark			\checkmark								
Potatoes (French fries; and boiled,										/								
baked, or mashed)										V								
Whole grains										\checkmark								
Refined grains										\checkmark								
Cereal fibre		\checkmark	\checkmark			\checkmark	\checkmark		\checkmark			\checkmark	\checkmark					\checkmark
Red meat							\checkmark			\checkmark								
Processed meats																		
Poultry							\checkmark											
Fish							\checkmark											
Sweets and desserts										\checkmark								
Potato chips										\checkmark								
Nuts							\checkmark			\checkmark								
Butter																		
Trans fat		\checkmark	\checkmark			\checkmark	\checkmark		\checkmark	\checkmark		\checkmark	\checkmark					\checkmark
PUFA:SFA ratio		\checkmark	\checkmark			\checkmark			\checkmark			~	\checkmark					\checkmark

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and metaanalysis of prospective cohort studies

Fried foods (consumed at home and						1					
away from home)						v					
Glycemic index										\checkmark	
Glycemic load										\checkmark	

Abbreviations: AHEI, Alternate Healthy Eating Index; ARIC, Atherosclerosis Risk in Communities Study; ATBC, Alpha-Tocophenol and Beta-Carotene Cancer Prevention Study; DASH, Dietary Approaches to Stop Hypertension; DLD, dyslipidemia; EPIC, The European Prospective Investigation of Cancer; HPFS, Health Professionals Follow-Up Study; HTN, hypertension; IWHS, Iowa Women's Health Study; LNCSBs, low- or no-calorie sweetened beverages; NHS, Nurses' Health Study; PUFA, poly-unsaturated fatty acids; SFA, saturated fatty acids; SSBs, Sugar-sweetened beverages; SUN, Sequimiento University of Navarra; WHI, Women's Health Initiative; WHS, Women's Health Study.

*Markers of obesity included baseline body weight, body mass index (BMI), waist circumference, percent body fat (%BF), change in BMI, waist-to-hip ratio, or change in body weight in the last 5 y prior to baseline data collection.

[†]Physical activity was measured as metabolic equivalent task hours per week, activity metabolic equivalent index score, and total energy expenditure.

[‡]Alcohol intake was only used as a prespecified variable for studies examining incidence of CVD.

 \checkmark indicates variables adjusted for in the included model of primary study outcomes in the original article.

 $\sqrt{9}$ indicates variables adjusted due to the nature of the cohort (i.e., single-sex cohort).

 \checkmark^{\parallel} indicates variables adjusted for only in females.

 $\sqrt{9}$ indicates variables that measured baseline and change from baseline values.

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and metaanalysis of prospective cohort studies

Supplementary Table 5A. Newcastle-Ottawa Scale (NOS) for assessing the quality of cohort comparisons using change analysis presented by cohort comparisons.

Cohort comparison	Selection [*]	Outcome [†]	Comparability [‡]	Total [§]
HPFS (Drouin-Chartier (4))	3	3	2	8
HPFS (Mozzafarian (1))	3	2	2	7
HPFS (Pan (5))	3	2	2	7
HPFS (Smith (2))	3	2	1	6
NHS (Drouin-Chartier (4))	3	3	2	8
NHS (Mozzafarian (1))	3	2	2	7
NHS (Pan (5))	3	2	2	7
NHS (Smith (2))	3	2	1	6
NHS II (Drouin-Chartier (4))	3	3	2	8
NHS II (Mozzafarian (1))	3	2	2	7
NHS II (Pan (5))	3	2	2	7
NHS II (Smith (2))	3	2	1	6
Mexican Teachers' Cohort (Stern (6))	3	2	1	6
PREMIER (Chen (7))	3	3	1	7

Abbreviations: HPFS, Health Professionals Follow-Up Study; NHS, Nurses' Health Study.

*Maximum 4 points were awarded for cohort representativeness, selection of non-exposed cohort, ascertainment of exposure assessment, and demonstration outcome not present at baseline.

[†]Maximum 3 points were awarded for follow-up length, adequacy of follow-up, and outcome assessment.

^{*}Maximum 2 points were awarded for controlling for the pre-specified primary confounding variable (age) and additional confounding variables (sex, markers of adiposity, smoking, energy intake, physical activity, family history).

[§]A maximum of 9 points could be awarded. Cohort were adjudged high (score \geq 7), moderate (score = 6) or low (score \leq 5) study quality.

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and metaanalysis of prospective cohort studies

Cohort comparison	Selection [*]	Outcome [†]	Comparability[‡]	Total [§]
A to Z (Stookey (8))	3	3	1	7
ARIC – Females (Keller (9))	3	3	2	8
ARIC – Males (Keller (9))	3	3	2	8
ATBC (Keller (9))	3	3	2	8
EPIC-Norfolk (O'Connor (10))	4	3	2	9
HPFS (Drouin-Chartier (4))	3	3	2	8
HPFS (Keller (9))	3	3	2	8
HPFS & NHS (Bernstein (11))	3	3	2	8
HPFS & NHS (Malik (12))	3	3	2	8
HPFS, NHS & NHS II (Pan (5))	3	3	2	8
IWHS (Keller (9))	3	3	2	8
NHS (Drouin-Chartier (4))	3	3	2	8
NHS80 (Keller (9))	3	3	2	8
NHS86 (Keller (9))	3	3	2	8
NHS II (Drouin-Chartier (4))	3	3	2	8
NHS II (Pan (13))	3	3	2	8
SUN (Fresan (14))	3	2	2	7
WHI (Huang (15))	3	2	2	7
WHS (Keller (9))	3	3	2	8

Supplementary Table 5B. Newcastle-Ottawa Scale (NOS) for assessing the quality of cohorts using substitution analysis presented by cohort comparisons.

Abbreviations: ARIC, Atherosclerosis Risk in Communities Study; ATBC, Alpha-Tocophenol and Beta-Carotene Cancer Prevention Study; EPIC, The European Prospective Investigation of Cancer; HPFS, Health Professionals Follow-Up Study; IWHS, Iowa Women's Health Study; NHS, Nurses' Health Study; SUN, Sequimiento University of Navarra; WHI, Women's Health Initiative; WHS, Women's Health Study.

*Maximum 4 points awarded for cohort representativeness, selection of non-exposed cohort, ascertainment of exposure assessment, and demonstration outcome not present at baseline.

[†]Maximum 3 points awarded for follow-up length, adequacy of follow-up, and outcome assessment.

^{*}Maximum 2 points awarded for controlling for the pre-specified primary confounding variable (age) and additional confounding variables (sex, markers of adiposity, smoking, energy intake, physical activity, family history, alcohol intake).

[§]A maximum of 9 points could be awarded. Cohort were adjudged high (score \geq 7), moderate (score = 6) or low (score \leq 5) study quality.

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and metaanalysis of prospective cohort studies

Supplementary Table 6A. Grading of Recommendations Assessment, Development, and Evaluation (GRADE) Assessment for Outcomes using change analysis.

				Quality assess	nent				Effect	Quality Importance
Outcomes	No. of cohort comparisons	No. of participants	Risk of bias/study quality	Inconsistency	Indirectness	Imprecision	Publication bias	Other considerations including upgrades	Effect Estimate [*] [95% CI]	
				Chang	e in LNCSB intake	e (Increasing 330	mL/day)			
Body Weight (kg/y)	5 (2; 6; 7)	129,210	Not serious	Serious [†]	Not serious	Not serious	Not serious [‡]	Dose-response association [§]	MD: -0.008 [-0.014, -0.002]	⊕⊕⊖⊖ LOW ^{↑,§} Due to downgrade for serious inconsistency and upgrade for dose- response association
Waist Circumference (cm/y)	1 (6)	9,294	Not serious	Not serious ^{††}	Serious ^I	Serious	Not serious‡	Dose-response association [§]	MD: -1.15 [-2.34, -0.045]	⊕⊕⊖⊖ LOW ^{I,¶,§} Due to downgrade for serious indirectness and imprecision, and upgrade for dose- response association
Risk of T2D	3 (4)	192,352	Not serious	Not serious ^{†††}	Serious ^{II}	Serious ^{¶¶}	Not serious [‡]	None ⁸	RR: 1.02 [0.99, 1.06]	UERY LOW ^{II,¶¶} Due to downgrade for serious indirectness and imprecision

Abbreviations: MD, mean difference; MID, minimally important difference; RR, risk ratio; T2D, Type 2 Diabetes Mellitus.

* Effect estimate was pooled and expressed as mean difference (MD) or risk ratios (RR).

[†] Downgrade for serious inconsistency as there was evidence of substantial heterogeneity ($I^2=66\%$, $P_Q=0.02$). Although the removal of NHS II (2) ($I^2=50\%$, $P_Q=0.11$) during sensitivity analysis partially explained the heterogeneity, the presence of residual heterogeneity could not be excluded. The removal of HFS (2) (MD: -0.004 kg/y, [95%CI: -0.011, 0.002]) and NHS (2) (-0.014 kg/y, [-0.022, 0.006]) altered the significance of the association.

^{††} No downgrade for inconsistency as only 1 cohort comparison was available for analysis.

^{†††} No downgrade for serious inconsistency as the presence of inter-study heterogeneity ($I^2=84\%$, $P_Q<0.01$) was explained by the removal of NHS II (4) ($I^2=0\%$, $P_Q=0.60$) during sensitivity analysis.

* No downgrade for publication bias, as publication bias could not be assessed due to lack of power for assessing funnel plot asymmetry and small study effects (<10 cohort comparisons included in the meta-analysis).

[§] Change analysis is a dose-response model where the cardiometabolic outcome is assessed against the increasing beverage (1 serving) intake over time. When the association was statistically significant, we applied an upgrade for dose-response association.

^{II} Downgrade for serious indirectness as only 1 cohort comparison of predominantly well-educated, female teachers in Mexico was available for analysis, limiting the generalizability of the outcome to a diverse European population with or at risk for diabetes.

Downgrade for serious indirectness as only 2 cohort comparisons of predominantly Caucasian, well-educated, health professionals in the USA were available for analysis, limiting the generalizability of the outcome to a diverse European population with or at risk for diabetes.

¹ Downgrade for serious imprecision as the upper bound of 95% CI (MD: 0 cm) includes clinically unimportant effects (MID: -2 cm to 2 cm), while the lower bound of the 95% CI (MD: -2.29 cm) includes clinically important benefit (MID: < -2 cm).

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and metaanalysis of prospective cohort studies

¹¹ Downgrade for serious imprecision as the upper bound of 95% CI (RR: 1.06) includes clinically important harm (RR: <1.05), while the lower bound of the 95% CI (RR: 0.99) includes clinically unimportant risk estimates (RR: 0.95 to 1.05).

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and metaanalysis of prospective cohort studies

Supplementary Table 6B. Grading of Recommendations Assessment, Development, and Evaluation (GRADE) Assessment for Outcomes using substitution analysis.

				Quality assess	ment				Effect	Quality Importance
Outcomes	No. of cohort comparisons	No. of participants	Risk of bias/study quality	Inconsistency	Indirectness	Imprecision	Publication bias	Other considerations including upgrades	Effect Estimate [*] [95% CI]	
				Substitu	tion of LNCSBs	for SSBs ("Inten	ded Substitution")		
Body Weight (kg/y)	3 (8; 13; 14)	165,579	Not serious	Not serious [†]	Not serious	Not serious	Not serious [‡]	Dose-response association [§]	MD: -0.12 [-0.14, -0.10]	⊕⊕⊕⊖ MODERATE [§] No downgrades and upgrade for dose- response association
Waist Circumference (cm/y)	1 (8)	173	Not serious	Not serious ^{††}	Serious ⁱ	Serious [¶]	Not serious [‡]	None [§]	MD: -1.83 [-3.70, 0.05]	⊕⊖⊖⊖ VERY LOW ^{I,¶} Due to downgrade for serious indirectness and imprecision
%BF (%/y)	1 (8)	173	Not serious	Not serious ^{††}	Serious ⁱ	Serious [¶]	Not serious [‡]	None [§]	MD: -0.96 [-2.32, 0.41]	⊕⊖⊖⊖ VERY LOW ¹ ¶ Due to downgrade for serious indirectness and imprecision
OB** Incidence	1 (14)	15,765	Not serious	Not serious ^{††}	Serious ^{II}	Not serious	Not serious [‡]	Dose-response association [§]	RR: 0.88 [0.88, 0.89]	⊕⊕⊖⊖ LOW ^{II§} Due to downgrade for serious indirectness
Risk of T2D	5 (4; 10; 13; 15)	281,855	Not serious	Serious ^{†††}	Not serious	Not serious	Not serious [‡]	None [§]	RR: 0.99 [0.96, 1.01]	⊕⊖⊖⊖ VERY LOW ^{†††} Due to downgrade for serious inconsistency and upgrade for dose- response association
CHD Events	6 (9)	233,676	Not serious	Not serious ^{††††}	Not serious	Serious ^{¶¶}	Not serious [‡]	Dose-response association [§]	RR: 0.89 [0.81, 0.98]	Due to downgrade for serious imprecision and upgrade for dose- response analysis
Risk of Stroke	1 (11)	127,456	Not serious	Not serious ^{††}	Serious ^{III}	Serious ^{¶¶¶}	Not serious [‡]	None [§]	RR: 1.03 [0.93, 1.14]	⊕⊖⊖⊖ VERY LOW ^{III,} Due to downgrade for serious indirectness and imprecision
CHD Mortality	5 (9)	220,805	Not serious	Not serious ^{†††††}	Not serious	Serious	Not serious [‡]	None [§]	RR: 0.95 [0.81, 1.11]	⊕⊖⊖⊖ VERY LOW ^{™™} Due to downgrade for serious imprecision
CVD Mortality	1 (12)	118,363	Not serious	Not serious ^{††}	Serious ^Ⅲ	Serious	Not serious [‡]	Dose-response association [§]	RR: 0.95 [0.90, 0.99]	Due to downgrade for serious indirectness and imprecision, and upgrade for dose-response association
Total Mortality	1 (12)	118,363	Not serious	Not serious ^{††}	Serious ^{III}	Serious	Not serious [‡]	Dose-response association [§]	RR: 0.96 [0.94, 0.98]	Due to downgrade for serious indirectness and imprecision, and upgrade for dose-response association

				Substitution of	Water for SSBs	s ("Standard of Ca	are Substitution'	")		
Body Weight (kg/y)	3 (5; 8; 13; 14)	165,579	Not serious	Serious ^{†††††††}	Not serious	Not serious	Not serious [‡]	Dose-response association [§]	MD: -0.10 [-0.13, -0.06]	⊕⊖⊖⊖ LOW ^{+++++§} Due to downgrade for serious inconsistency and upgrade for dose-response association
Waist Circumference (cm/y)	1 (8)	173	Not serious	Not serious††	Serious ¹	Serious	Not serious [‡]	Dose-response association [§]	MD: -2.71 [-4.27, -1.15]	Due to downgrade for serious indirectness and imprecision, and upgrade for dose-response association
%BF (%)	1 (8)	173	Not serious	Not serious††	Serious ¹	Serious	Not serious [‡]	Dose-response association [§]	MD: -1.51 [-2.61, -0.42]	⊕⊖⊖⊖ LOW ^{1,} IIIIIIII [§] Due to downgrade for serious indirectness and imprecision, and upgrade for dose-response association
OB [*] Incidence	1 (14)	15,765	Not serious	Not serious ^{††}	Serious ^{II}	Serious	Not serious [‡]	Dose-response association [§]	RR: 0.85 [0.75, 0.97]	Due to downgrade for serious indirectness and imprecision, and upgrade for dose-response association
Risk of T2D	3 (4; 10; 13; 15)	281,855	Not serious	Not serious ^{††††††††}	Not serious	Serious	Not serious [‡]	Dose-response association [§]	RR: 0.96 [0.94, 0.98]	⊕⊖⊖⊖ LOW ^{111111111§} Due to downgrade for serious imprecision, and upgrade for dose-response association
Risk of Stroke	1 (11)	127,456	Not serious	Not serious ^{††}	Serious	Serious	Not serious [‡]	None [§]	RR: 1.00 [0.94, 1.06]	⊕⊖⊖⊖ VERY LOW ^{III,} The serious indirectness and imprecision
			1	Substitution	of LNCSBs for	Water ("Reference	Substitution")	1	1	
Body Weight (kg/y)	1 (14)	173	Not serious	Not serious ^{††}	Serious ^{II}	Not serious	Not serious [‡]	None [§]	MD: 0.08 [-0.11, 0.27]	⊕⊖⊖⊖ VERY LOW Due to downgrade for serious indirectness
OB [*] Incidence	1 (14)	15,765	Not serious	Not serious ^{††}	Serious ^{II}	Serious ¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹	Not serious [‡]	None [§]	RR: 1.19 [0.94, 1.50]	⊕⊖⊖ VERY LOW ^{II}
Risk of T2D	4 (4; 15)	257,202	Not serious	Serious ^{††††††}	Not serious	Not serious	Not serious [‡]	None [§]	RR: 1.00 [0.98, 1.02]	⊕⊖⊖⊖ VERY LOW ^{††††††} Due to downgrade for serious inconsistency
Risk of Stroke	1 (11)	127,456	Not serious	Not serious ^{††}	Serious	Serious	Not serious [‡]	None [§]	RR: 1.03 [0.98, 1.09]	⊕⊖⊖⊖ VERY LOW ^{III,} Interference of the serious indirectness and imprecision

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and metaanalysis of prospective cohort studies

Abbreviations: BMI, body mass index; CVD, cardiovascular disease; MD, mean difference; MID, minimally important difference; RR, risk ratio; T2D, Type 2 Diabetes Mellitus; OB, Obesity; %BF, Percent body fat.

Effect estimate was pooled and expressed as mean difference (MD) or risk ratios (RR). ** OB was defined as having a BMI of $>30 \text{ kg/m}^2$. t No downgrade for inconsistency as there was no evidence of substantial inter-study heterogeneity ($I^2=17\%$, $P_0=0.30$). †† No downgrade for inconsistency, as only 1 cohort comparison was available for analysis. ††† Downgrade for serious inconsistency as there was evidence of substantial inter-study heterogeneity (I²=69%, P₀=0.01); and sensitivity analysis could not explain the heterogeneity. †††† No downgrade for serious inconsistency, as there was no evidence of substantial inter-study heterogeneity ($I^2=28\%$, $P_{\Omega}=0.22$). ***** No downgrade for serious inconsistency, as there was no evidence of substantial inter-study heterogeneity ($1^2=36\%$, $P_0=0.18$). ***** Downgrade for serious inconsistency as there was evidence of substantial inter-study heterogeneity ($I^2=83\%$, $P_0 < 0.01$); and sensitivity analysis could not explain the heterogeneity. ****** Downgrade for serious inconsistency as there was evidence of substantial inter-study heterogeneity ($I^2=82\%$, $P_0<0.01$); and sensitivity analysis could not explain the heterogeneity. ****** No downgrade for serious inconsistency as the presence of inter-study heterogeneity ($I^2=79\%$, $P_0<0.01$) was explained by the removal of HPFS, NHS, and NHS II cohort comparison (4) ($I^2=0\%$, $P_0=0.76$) during sensitivity analysis. ŧ No downgrade for publication bias, as publication bias could not be assessed due to lack of power for assessing funnel plot asymmetry and small study effects (<10 cohort comparisons included in the meta-analysis). § Substitution analysis is a dose-response model where a potential change is estimated for substituting 1-serving of beverage A against beverage B. It is done by examining the difference between regression coefficients of the two beverages included as continuous (linear) terms of dose-intake. When the association was statistically significant, we applied an upgrade for dose-response association. Ш Downgrade for serious indirectness as only 1 cohort comparison with obese female participants in a weight-loss trial was available for analysis, limiting the generalizability of the outcome to a diverse European population with or at risk for diabetes. Downgrade for serious indirectness as only 1 cohort comparison with participants from Spain was available for analysis, limiting the generalizability of the outcome to a diverse European population with or at risk for diabetes. Downgrade for serious indirectness as only 1 cohort comparison of predominantly Caucasian, well-educated, health professionals in the USA were available for analysis, limiting the generalizability of the outcome to a diverse European population with or at risk for diabetes. ¶ Downgrade for serious imprecision as the upper bound of 95% CI (0.05 cm) includes clinically unimportant effects (MID: -2 cm to 2 cm), while the lower bound of the 95% CI (-3.70 cm) includes clinically important benefit (MID: < -2 cm). 11 Downgrade for serious imprecision as the upper bound of 95% CI (0.41%) includes clinically unimportant effects (MID: -2% to 2%), while the lower bound of 95% CI (-2.32%) includes clinically important benefit (MID: < -2%). 999 Downgrade for serious imprecision as the upper bound of the 95% CI (RR: 0.98) includes clinically unimportant risk estimates (RR: 0.95 to 1.05), while the lower bound of 95% CI (RR: 0.81) includes clinically important benefit (RR: <0.95). 1111 Downgrade for serious imprecision as the upper bound of 95% CI (RR: 1.14) includes clinically important harm (RR >1.05), while the lower bound of 95% CI (RR: 0.93) includes clinically unimportant risk estimates (RR: 0.95 to 1.05). 11111 Downgrade for serious imprecision as the upper bound of 95% CI (RR: 1.11) includes clinically important harm (RR > 1.10), while the lower bound of 95% CI (RR: 0.81) includes clinically important benefit (RR: <0.95). 111111 Downgrade for serious imprecision as the upper bound of 95% CI (RR: 0.99) includes clinically unimportant risk estimates (RR: 0.95 to 1.05) while the lower bound of 95% CI (RR: 0.90) includes clinically important benefit (RR: <0.95). 1111111 Downgrade for serious imprecision as the upper bound of 95% CI (RR: 0.98) includes clinically unimportant risk estimates (RR: 0.95 to 1.05) while the lower bound of 95% CI (RR: 0.94) includes clinically important benefit (RR: <0.95). 11111111 Downgrade for serious imprecision as the upper bound of 95% CI (RR: 1.50) includes clinically important harm (RR: >1.05), while the lower bound of 95% CI (RR: 0.94) includes clinically important benefit (RR: <0.95). 1111111111 Downgrade for serious imprecision as the upper bound of 95% CI (RR: 1.09) includes clinically important harm (RR: >1.05), while the lower bound of 95% CI (RR: 0.98) includes clinically unimportant risk estimates (RR: 0.95 to 1.05). 11111111111 Downgrade for serious imprecision as the upper bound of 95% CI (MD: -1.15 cm) includes clinically unimportant effects (MID: -2 cm to 2 cm), while the lower bound of 95% CI (MD: -4.27%) includes clinically important risk benefit (MID:< -2%).

- Downgrade for serious imprecision as the upper bound of 95% CI (MD: -0.42%) includes clinically unimportant effects (MID: -2% to 2%), while the lower bound of 95% CI (MD: -2.61%) includes clinically important risk benefit (MID:< -2%).
- Downgrade for serious imprecision as the upper bound of 95% CI (RR: 0.97) includes clinically unimportant risk estimates (RR: 0.95 to 1.05), while the lower bound of 95% CI (RR: 0.75) includes clinically important benefit (RR: <0.95).
- Downgrade for serious imprecision as the upper bound of 95% CI (RR: 0.98) includes clinically unimportant risk estimates (RR: 0.95 to 1.05) while the lower bound of 95% CI (RR: 0.94) includes clinically important benefit (RR: <0.95).
- Downgrade for serious imprecision as the upper bound of 95% CI (RR: 1.06) includes clinically important harm (RR: >1.05), while the lower bound of 95% CI (RR: 0.94) includes clinically important benefit (RR: <0.95).

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and metaanalysis of prospective cohort studies

				Qı	ality assessmer	ıt				Effect	Score
Outcomes	No. of cohort comparisons	Risk of bias, study quality and study limitations [*]	Precision**	Heterogeneity	Directness	Publication bias	Funding bias	Effect Size**	Dose Response	Effect Estimate [95% CI]***	Meta-evidence (Final point)
				Change in LNCS	B intake (Increa	ising 330 mL/da	y)				
Body Weight (kg/y)	5 (2; 6; 7)	1 (Mean NOS: 6.2)	1^{\dagger}	0‡	1	01	1¶	0**	1*	MD: -0.008 [-0.014, -0.002]	Low (5)
Waist Circumference (cm/y)	1 (6)	l (Mean NOS: 6)	$0^{\dagger\dagger}$	0‡‡	0§	01	1¶	0**	1*	MD: -1.15 [-2.34, -0.045]	Very low (3)
Risk of T2D	3 (4)	2 (Mean NOS: 8)	1 ^{†††}	0‡	0 ^{§§}	01	1¶	0***	0	RR: 1.02 [0.99, 1.06]	Low (4)

Supplementary Table 6C. NutriGRADE Assessment for Outcomes using change analysis.

Abbreviations: CI, confidence interval; MD, mean difference; MID, minimally important difference; NOS, Newcastle-Ottawa Scale; RR, risk ratio; T2D, Type 2 Diabetes Mellitus.

* Risk of bias was assessed using NOS shown in Supplementary Table 6A.

** Important benefit was defined as RR of <0.8 and harm RR of > 1.2 (16). For body weight and waist circumference, important benefit was defined as MID shown in **Supplementary Table 4** (i.e., body weight: -0.5 kg to 0.5 kg; waist circumference: -2 cm to 2 cm).

*** Effect estimate was pooled and expressed as mean difference (MD) or risk ratios (RR).

[†] 1 point was awarded because results from ≥500 participants were included, and the 95% CI excludes the null value.

^{††} No point was awarded because results from ≥500 participants were included, but 95% CI includes the null value and 95% CI fails to exclude important benefit (MD <-2 cm).

1 point was awarded because \geq 500 events were included, but 95% CI overlaps the null value and 95% CI excludes important benefit (RR <0.8) or harm (RR >1.2).

[‡] 0 point was awarded for exploring detected heterogeneity with sensitivity analysis (0.3 point) from 3 cohort comparisons (multiplier: 0)

^{‡‡} No point was awarded because heterogeneity could not be assessed due to only 1 cohort comparison available for analysis.

[§] No point was awarded because only 1 cohort comparison with female Mexican teachers was available for analysis.

^{§§} No point was awarded because only cohort comparisons with US healthcare professionals were available for analysis.

¹ No point was awarded as publication bias could not be assessed due to lack of power for assessing funnel plot asymmetry and small study effects.

1 point was awarded because all studies received funding from academic and/or research institutions.

No point was awarded because effect estimate showed small effect size (RR: 0.80 - 1.20).

* Change analysis is a dose-response model where the cardiometabolic outcome is assessed against the increasing beverage (1 serving) intake over time. When the association was statistically significant, 1 point was awarded for the dose-response association.

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and metaanalysis of prospective cohort studies

		Quality assessment (points; Max 10)								Effect	Score
Outcomes	No. of cohort comparisons	Risk of bias, study quality and study limitations*	Precision**	Heterogeneity	Directness	Publication bias	Funding bias	Effect Size**	Dose Response	Effect Estimate [95% CI]***	Meta-evidence (Final point)
			Su	bstitution of LNCS	SBs for SSBs ("	Intended Substi	tution")				
Body Weight (kg/y)	3 (8; 13; 14)	2 (Mean NOS: 7)	1^{\dagger}	0‡	1	01	1¶	0**	1*	MD: -0.12 [-0.14, -0.10]	Moderate (6)
Waist Circumference (cm/y)	1 (8)	2 (Mean NOS: 7)	$0^{\dagger\dagger}$	0‡‡	0§	01	1¶	0**	0	MD: -1.83 [-3.70, 0.05]	Very low (3)
%BF (%/y)	1 (8)	2 (Mean NOS: 7)	$0^{\dagger\dagger}$	0 ^{‡‡}	0§	01	11	0**	0	MD: -0.96 [-2.32, 0.41]	Very low (3)
OB **** Incidence	1 (14)	2 (Mean NOS: 7)	1^{\dagger}	0 ^{‡‡}	$0^{\S\S}$	01	11	0**	1*	RR: 0.88 [0.88, 0.89]	Low (5)
Risk of T2D	5 (4; 10; 13; 15)	2 (Mean NOS: 7.75)	1***	0‡	1	0^1	11	0**	0	RR: 0.99 [0.96, 1.01]	Low (5)
CHD Events	6 (9)	2 (Mean NOS: 8)	1^{\dagger}	0.5***	1	01	1¶	0**	1*	RR: 0.89 [0.81, 0.98]	Moderate (6.5)
Risk of Stroke	1 (11)	2 (Mean NOS: 8)	1***	0 ^{‡‡}	0\$\$\$	01	1¶	0**	0	RR: 1.03 [0.93, 1.14]	Low (4)
CHD Mortality	5 (9)	2 (Mean NOS: 8)	1***	0*****	1	01	11	0**	0	RR: 0.95 [0.81, 1.11]	Low (5)
CVD Mortality	1 (12)	2 (Mean NOS: 8)	1^{\dagger}	0‡	0888	01	11	0**	1*	RR: 0.95 [0.90, 0.99]	Low (5)
Total Mortality	1 (12)	2 (Mean NOS: 8)	1^{\dagger}	0‡	0888	01	11	0**	1*	RR: 0.96 [0.94, 0.98]	Low (5)
			Subst	itution of Water fo	r SSBs ("Stand	lard of Care Sub	ostitution")		1		
Body Weight (kg/y)	3 (5; 8; 13; 14)	2 (Mean NOS: 7.33)	1^{\dagger}	0‡	1	01	1¶	0**	1*	MD: -0.10 [-0.13, -0.06]	Moderate (6)
Waist Circumference (cm/y)	1 (8)	2 (Mean NOS: 7)	$0^{\dagger\dagger}$	0 ^{‡‡}	$0^{\$}$	01	1¶	0***	1*	MD: -2.71 [-4.27, -1.15]	Low (4)
%BF (%)	1 (8)	2 (Mean NOS: 7)	$0^{\dagger\dagger}$	0 ^{‡‡}	0 [§]	01	1 1	0**	1*	MD: -1.51 [-2.61, -0.42]	Low (4)
OB**** Incidence	1 (14)	2 (Mean NOS: 7)	1^{\dagger}	0 ^{‡‡}	088	01	11	0**	1*	RR: 0.85 [0.75, 0.97]	Low (5)
Risk of T2D	3 (4; 10; 13; 15)	2 (Mean NOS: 7.33)	1†	0‡	1	01	11	0**	1*	RR: 0.96 [0.94, 0.98]	Low (6)
Risk of Stroke	1 (11)	2 (Mean NOS: 8)	1***	0 ^{‡‡}	0 ^{§§§}	01	1¶	0**	0	RR: 1.00 [0.94, 1.06]	Low (4)
			Sub	stitution of LNCS	Bs for Water ("	Reference Subs	titution")		1		
Body Weight (kg/y)	1 (14)	2 (Mean NOS: 7)	1***	0 ^{‡‡}	0 ^{§§}	01	1¶	0**	0	MD: 0.08 [-0.11, 0.27]	Low (4)
OB**** Incidence	1 (14)	2 (Mean NOS: 7)	0****	0 ^{‡‡}	0 ^{§§}	01	1¶	0**	0	RR: 1.19 [0.94, 1.50]	Very low (3)
Risk of T2D	4 (4; 15)	2 (Mean NOS: 7.5)	1***	0‡	1	01	1¶	0***	0	RR: 1.00 [0.98, 1.02]	Low (5)

Supplementary Table 6D. NutriGRADE Assessment for Outcomes using substitution analysis.

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and metaanalysis of prospective cohort studies

Risk of S	troke	1 (11)	2 (Mean NOS: 8)	$1^{\dagger\dagger\dagger}$	0 ^{‡‡}	0 ^{§§§}	01	11	0**	0	RR: 1.03 [0.98, 1.09]	Low (4)
A	bbreviati	ons: BMI, body	mass index; CVD, card	iovascular dis	sease; MD, mean	difference; M	ID, minimally i	mportant differ	ence; NOS	5, Newcastle-Ot	tawa Scale; RR, ris	k ratio;
T	2D, Type	e 2 Diabetes Mell	itus; OB, Obesity; %BF	, Percent bod	y fat.			-				
*	Risk of b	ias was assessed	using NOS shown in Su	applementary	Table 6A.							
**]	Importan	t benefit was def	ined as RR of <0.8 and l	harm RR of >	1.2 (16). For bod	y weight, wai	st circumference	e, and %BF, im	portant ber	nefit was define	d as MID shown in	
5	Supplem	entary Table 4	i.e., body weight: -0.5 k	kg to 0.5 kg; v	vaist circumferend	ce: -2 cm to 2	cm; %BF: -2%	to 2%).	•			
***	Effect es	timate was poole	d and expressed as mear	n difference (1	MD) or risk ratios	(RR).		,				
**** (OB was o	defined as having	a BMI of ≥ 30 kg/m ² .		,	. ,						
† 1	1 point w	as awarded beca	use results from ≥ 500 pa	articipants or	≥500 events were	included, and	the 95% CI exc	cludes the null	value.			
††]	No point	was awarded bed	cause results from <500	participants v	vere included in th	ne analysis.						
†††	1 point w	as awarded beca	use ≥500 events were in	cluded, but 9	5% CI overlaps th	e null value a	nd 95% CI exclu	udes important	benefit (RI	R <0.8) or harm	(RR >1.2).	
††††]	No point	was awarded bed	ause 500 events were ir	ncluded, but 9	5% CI includes th	ne null value a	nd 95% CI fails	s to exclude imp	ortant harr	n (RR >1.2).	. ,	
* 0	point wa	as awarded for ex	ploring detected heterog	geneity with s	ensitivity analysis	s (0.3 point) fr	om 2-5 cohort c	comparisons (m	ultiplier: 0)		
‡‡]	Ño point	was awarded bed	ause heterogeneity coul	ld not be asses	ssed due to only 1	cohort comp	arison available	for analysis.	•	, ,		
^{‡‡‡} (0.5 point	was awarded for	reporting no important	heterogeneity	v (I ² <40%) from 6	cohort compa	arisons (multipli	ier: 1).				
^{‡‡‡‡} (0 point w	as awarded for re	eporting no important he	eterogeneity (I ² <40%) from 2-5	cohort comp	arisons (multipli	ier: 0).				
§ 1	No point	was awarded bed	cause only 1 cohort com	parison with	female obese fema	ale participant	s in a weight-lo	ss trial was ava	ilable for a	nalysis.		
§§]	No point	was awarded bed	cause only 1 cohort com	parison with	graduates from a S	Spanish unive	rsity was availal	ble for analysis.		-		
§§§]	No point	was awarded bed	cause only cohort compa	arisons from U	JS healthcare prof	fessional was	available for and	alysis.				
1	No point	was awarded as	publication bias could n	ot be assessed	due to lack of po	wer for assess	sing funnel plot	asymmetry and	l small stud	ly effects.		
٩ - 1	1 point w	as awarded beca	use all studies received	funding from	academic and/or i	research instit	utions.			-		
** 1	No point	was awarded bec	ause effect estimate sho	wed small eff	fect size (RR: 0.80) - 1.20).						
*	Substitut	ion analysis is a	dose-response model wł	nere a potentia	al change is estimated	ated for substi	tuting 1-serving	g of beverage A	against be	verage B. It is d	one by examining t	he

difference between regression coefficients of the two beverages included as continuous (linear) terms of dose-intake. When the association was statistically significant, 1 point was awarded for the dose-response association.

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

Supplementary Table 7. Minimum Important Difference (MID) used for the imprecision in GRADE assessments

Outcome	MID	Reference
Body weight	0.5 kg	Ge et al. (3)
%Body Fat	2%	Absolute reduction based on 5-7% weight loss being clinically
		meaningful
BMI	0.2 kg/m^2	Roughly equivalent to 0.5kg
Waist Circumference	2 cm	2 cm=1 full pant size
Risk of OW/OB, diabetes, CVD	RR: 0.95, 1.05	5% change in risk
events, or mortality		

Abbreviations: BMI, body mass index; CVD, Cardiovascular disease; GRADE, Grading of Recommendations Assessment, Development and Evaluation; MID, Minimally Important Differences; OB, obesity; OW, overweight.

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

SUPPLEMENTARY FIGURES

Supplementary Figure 1. Consort diagram outlining the summary of evidence search and selection for water substitution and cardiometabolic outcomes.



Of the 143 studies screened, 134 were excluded based on title and abstract review. The remaining 9 studies were reviewed in full. A total of 8 studies met the inclusion criteria and qualified for further analysis.

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

Supplementary Figure 2A. Relationship between increasing one serving (330 mL) of low-and nocalorie sweetened beverage (LNCSB) intake a day and change in body weight (kg) per year using a fixed-effects model.

Cohort Comparison			MD [95% CI]	Weight (%)
PREMIER (Chen 2009)	<	-0.23	3 [-0.47 to 0.01]	0.06
HPFS (Smith 2015)		-0.02	2 [-0.04 to -0.01]	18.03
NHS (Smith 2015)		-0.0	1 [-0.02 to 0.00]	36.41
NHS II (Smith 2015)		0.00	0 [-0.01 to 0.01]	45.48
Mexican Teachers' Cohort (Stern 2017)	<	→ 0.09	9 [-0.53 to 0.71]	0.01
Overall (Fixed-effects)	•	-0.0	1 [-0.01 to -0.00]	
Random-effects	•	-0.0	1 [-0.02 to 0.00]	
Heterogeneity: I ² = 65.68%, H ² = 2.91				
Test of $\theta_i = \theta_i$: Q(4) = 11.66, p = 0.02				
Test of $\theta = 0$: z = -2.58, p = 0.01				
	21 0 Protective Association	.1 .2 Adverse Association		

Fixed-effects inverse-variance model

The black diamond represents the pooled summary estimate. Inter-study heterogeneity was tested using the Cochran Q statistic at a significance level of $P_Q < 0.10$ and quantified by the I² statistic. An I² value $\geq 50\%$ was considered to indicate substantial heterogeneity. All results are presented as mean difference (MD) in body weight (kg) per year with 95% Confidence Intervals (CI) where estimable. Abbreviations: HPFS, Health Professionals Follow-Up Study; NHS, Nurses' Health Study.

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

Supplementary Figure 2B. Relationship between increasing one serving (330 mL) of low-and nocalorie sweetened beverage (LNCSB) intake a day and change in waist circumference (cm) per year using a fixed-effects model.

Cohort Comparison			MD [95% CI]	Weight (%)
Mexican Teachers' Cohort (Stern 2017) Overall Test of θ = 0: z = -1.98, p = 0.049	-4 -2 0 Protective Association	2 4 Adverse Association	-1.15 [-2.34 to -0.045] -1.15 [-2.34 to -0.045]	100.00

The black diamond represents the pooled summary estimate. Inter-study heterogeneity could not be assessed as only 1 cohort comparison was available for analysis. All results are presented as mean difference (MD) per year with 95% Confidence Intervals (CI) where estimable.

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

Supplementary Figure 2C. Relationship between increasing one serving (330 mL) of low-and nocalorie sweetened beverage (LNCSB) intake a day and type 2 diabetes (T2D) incidence using a fixed-effects model.



Fixed-effects inverse-variance model

The black diamond represents the pooled summary estimate. Inter-study heterogeneity was tested using the Cochran Q statistic at a significance level of $P_Q < 0.10$ and quantified by the I² statistic. An I² value $\geq 50\%$ was considered to indicate substantial heterogeneity. All results are presented as risk ratio (RR) with 95% Confidence Intervals (CI) where estimable. Abbreviations: HPFS, Health Professionals Follow-Up Study; NHS, Nurses' Health Study.

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

Supplementary Figure 3A. Relationship between substituting low-and no-calorie sweetened beverages (LNCSBs) for sugar-sweetened beverages (SSBs) and change in body weight (kg) per year using a fixed-effects model.



Fixed-effects inverse-variance model

The black diamond represents the pooled summary estimate. Inter-study heterogeneity was tested using the Cochran Q statistic at a significance level of $P_Q < 0.10$ and quantified by the I² statistic. An I² value $\geq 50\%$ was considered to indicate substantial heterogeneity. All results are presented as mean difference (MD) in body weight per year with 95% Confidence Intervals (CI) where estimable. Abbreviations: HPFS, Health Professionals Follow-Up Study; NHS, Nurses' Health Study; SUN, Sequimiento University of Navarra.

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

Supplementary Figure 3B. Relationship between substituting low-and no-calorie sweetened beverages (LNCSBs) for sugar-sweetened beverages (SSBs) and change in waist circumference (cm) per year.



The black diamond represents the pooled summary estimate. Inter-study heterogeneity could not be assessed as only 1 cohort comparison was available for analysis. All results are presented as mean difference (MD) per year with 95% Confidence Intervals (CI) where estimable.

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

Supplementary Figure 3C. Relationship between substituting low-and no-calorie sweetened beverages (LNCSBs) for sugar-sweetened beverages (SSBs) and change in percent body fat (%) per year.



The black diamond represents the pooled summary estimate. Inter-study heterogeneity could not be assessed as only 1 cohort comparison was available for analysis. All results are presented as mean difference (MD) per year with 95% Confidence Intervals (CI) where estimable.

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

Supplementary Figure 3D. Relationship between substituting low-and no-calorie sweetened beverages (LNCSBs) for sugar-sweetened beverages (SSBs) and obesity (OB) incidence.



The black diamond represents the pooled summary estimate. Inter-study heterogeneity could not be assessed as only 1 cohort comparison was available for analysis. An I² value \geq 50% was considered to indicate substantial heterogeneity. All results are presented as risk ratio (RR) with 95% Confidence Intervals (CI) where estimable. Abbreviations: SUN, Sequimiento University of Navarra.

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

Supplementary Figure 3E. Relationship between substituting low-and no-calorie sweetened beverages (LNCSBs) for sugar-sweetened beverages (SSBs) and type 2 diabetes (T2D) incidence using a fixed-effects model.

Cohort Comparison		RR [95% CI]	
EPIC Norfolk (O'Connor 2015)		0.93 [0.76 to 1.13]	1.47
HPFS (Drouin-Chartier 2019)		1.05 [0.98 to 1.13]	11.78
NHS (Drouin-Chartier 2019)		1.03 [0.99 to 1.07]	33.59
NHS II (Drouin-Chartier 2019)		0.95 [0.92 to 0.99]	41.27
WHI (Huang 2017)		0.94 [0.88 to 1.01]	11.89
Overall (Fixed-effects)	•	0.99 [0.96 to 1.01]	
Random-effects	•	0.99 [0.94 to 1.04]	
Heterogeneity: $I^2 = 69.14\%$, $H^2 = 3.24$			
Test of $\theta_i = \theta_i$: Q(4) = 12.96, p = 0.01			
Test of $\theta = 0$: z = -1.19, p = 0.23			
	0.75 1.00 1.25 Protective Association Adverse Assoc	siation	

Fixed-effects inverse-variance model

The black diamond represents the pooled summary estimate. Inter-study heterogeneity was tested using the Cochran Q statistic at a significance level of $P_Q < 0.10$ and quantified by the I² statistic. An I² value $\geq 50\%$ was considered to indicate substantial heterogeneity. All results are presented as risk ratio (RR) with 95% Confidence Intervals (CI) where estimable. Abbreviations: EPIC, The European Prospective Investigation of Cancer; HPFS, Health Professionals Follow-Up Study; NHS, Nurses' Health Study; WHI, Women's Health Initiative.

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

Supplementary Figure 3F. Relationship between substituting low-and no-calorie sweetened beverages (LNCSBs) for sugar-sweetened beverages (SSBs) and coronary heart disease (CHD) incidence using DerSimonian-Laird random-effects model.



Random-effects DerSimonian-Laird model

The black diamond represents the pooled summary estimate. Inter-study heterogeneity was tested using the Cochran Q statistic at a significance level of $P_Q < 0.10$ and quantified by the I² statistic. An I² value $\geq 50\%$ was considered to indicate substantial heterogeneity. All results are presented as risk ratio (RR) with 95% Confidence Intervals (CI) where estimable. Abbreviations: ARIC, Atherosclerosis Risk in Communities Study; HPFS, Health Professionals Follow-Up Study; NHS, Nurses' Health Study; WHS: Women's Health Study.

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

Supplementary Figure 3G. Relationship between substituting low-and no-calorie sweetened beverages (LNCSBs) for sugar-sweetened beverages (SSBs) and stroke incidence.

Cohort Comparison		RR [95% CI]	Welght (%)
HPFS & NHS (Bernstein 2012) Overall Test of θ = 0: z = 0.57, p = 0.57	0.80 1.00 1.20 Protective Association Adverse Associa	1.03 [0.93 to 1.14] 1.03 [0.93 to 1.14] 	100.00

The black diamond represents the pooled summary estimate. Inter-study heterogeneity could not be assessed as only 1 cohort comparison was available for analysis. All results are presented as risk ratio (RR) with 95% Confidence Intervals (CI) where estimable. Abbreviations: HPFS, Health Professionals Follow-Up Study; NHS, Nurses' Health Study

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

Supplementary Figure 3H. Relationship between substituting low-and no-calorie sweetened beverages (LNCSBs) for sugar-sweetened beverages (SSBs) and the risk of coronary heart disease (CHD) mortality using a fixed-effects model.



The black diamond represents the pooled summary estimate. Inter-study heterogeneity was tested using the Cochran Q statistic at a significance level of $P_Q < 0.10$ and quantified by the I² statistic. An I² value $\geq 50\%$ was considered to indicate substantial heterogeneity. All results are presented as risk ratio (RR) with 95% Confidence Intervals (CI) where estimable. Abbreviations: ARIC, Atherosclerosis Risk in Communities Study; HPFS, Health Professionals Follow-Up Study; IWHS, Iowa Women's Health Study; NHS, Nurses' Health Study.

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

Supplementary Figure 3I. Relationship between substituting low-and no-calorie sweetened beverages (LNCSBs) for sugar-sweetened beverages (SSBs) and the risk of total cardiovascular disease (CVD) mortality.



The black diamond represents the pooled summary estimate. All results are presented as risk ratio (RR) with 95% Confidence Intervals (CI) where estimable. Abbreviations: ARIC, Atherosclerosis Risk in Communities Study; HPFS, Health Professionals Follow-Up Study; IWHS, Iowa Women's Health Study; NHS, Nurses' Health Study.

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

Supplementary Figure 3J. Relationship between substituting low-and no-calorie sweetened beverages (LNCSBs) for sugar-sweetened beverages (SSBs) and the risk of total mortality.



The black diamond represents the pooled summary estimate. Inter-study heterogeneity could not be assessed as only 1 cohort comparison was available for analysis. All results are presented as risk ratio (RR) with 95% Confidence Intervals (CI) where estimable. Abbreviations: HPFS, Health Professionals Follow-Up Study; NHS, Nurses' Health Study

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

Supplementary Figure 4A. Relationship between substituting water for sugar-sweetened beverages (SSBs) and change in body weight (kg) per year using a fixed-effects model.

Cohort Comparison			MD [95% CI]	Weight (%)
A to Z (Stookey 2008)	<		-2.39 [-4.11 to -0.67]	0.04
HPFS, NHS, NHS II (Pan 2013)			-0.12 [-0.16 to -0.08]	64.08
SUN (Fresan 2016)		•	-0.05 [-0.11 to 0.00]	35.88
Overall (Fixed-effects)	•		-0.10 [-0.13 to -0.06]	
Random-effects	•		-0.10 [-0.20 to 0.01]	
Heterogeneity: l ² = 81.75%, H ² = 5.48				
Test of $\theta_i = \theta_i$: Q(2) = 10.96, p = 0.00				
Test of $\theta = 0$: z = -5.80, p = 0.00				
	-2 -1	0 1	2	
	Protective Association	Adverse Associat	tion	

Fixed-effects inverse-variance model

The black diamond represents the pooled summary estimate. Inter-study heterogeneity was tested using the Cochran Q statistic (χ^2) at a significance level of P_Q<0.10 and quantified by the I² statistic. An I² value \geq 50% was considered to indicate substantial heterogeneity. All results are presented as mean difference (MD) per year with 95% Confidence Intervals (CI) where estimable. Abbreviations: HPFS, Health Professionals Follow-Up Study; NHS, Nurses' Health Study; SUN, Sequimiento University of Navarra.

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

Supplementary Figure 4B. Relationship between substituting water for sugar-sweetened beverages (SSBs) and change in waist circumference (cm) per year.



The black diamond represents the pooled summary estimate. Inter-study heterogeneity could not be assessed as only 1 cohort comparison was available for analysis. All results are presented as risk ratio (RR) with 95% Confidence Intervals (CI) where estimable.

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

Supplementary Figure 4C. Relationship between substituting water for sugar-sweetened beverages (SSBs) and change in percent body fat (%) per year.



The black diamond represents the pooled summary estimate. Inter-study heterogeneity could not be assessed as only 1 cohort comparison was available for analysis. All results are presented as mean difference (MD) per year with 95% Confidence Intervals (CI) where estimable.

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

Supplementary Figure 4D. Relationship between substituting water for sugar-sweetened beverages (SSBs) and obesity (OB) incidence.



The black diamond represents the pooled summary estimate. Inter-study heterogeneity could not be assessed as only 1 cohort comparison was available for analysis. An I² value \geq 50% was considered to indicate substantial heterogeneity. All results are presented as risk ratio (RR) with 95% Confidence Intervals (CI) where estimable. Abbreviations: SUN, Sequimiento University of Navarra.

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

Supplementary Figure 4E. Relationship between substituting water for sugar-sweetened beverages and the risk of type 2 diabetes (T2D) using a fixed-effects model.

Cohort Comparison		RR	[95% CI]	Weight (%)
EPIC Norfolk (O'Connor 2015) HPFS, NHS, NHS II (Drouin-Chartier 2019)		0.88 [0 0.98 [0	.78 to 1.00] .96 to 1.01]	3.56 79.53
WHI (Huang 2017)		0.90 [0	.85 to 0.95]	16.91
Overall (Fixed-effects)	•	0.96 [0	.94 to 0.98]	
Random-effects Heterogeneity: $I^2 = 78.93\%$, $H^2 = 4.75$ Test of $\theta_i = \theta_j$: Q(2) = 9.49, p = 0.01 Test of $\theta = 0$: z = -3.29, p = 0.00		0.93 [0	.86 to 1.00]	
	0.75 1.00 Protective Association) 1.25 Adverse Association		

Fixed-effects inverse-variance model

The black diamond represents the pooled summary estimate. Inter-study heterogeneity was tested using the Cochran Q statistic (χ^2) at a significance level of P_Q<0.10 and quantified by the I² statistic. An I² value \geq 50% was considered to indicate substantial heterogeneity. All results are presented as risk ratio (RR) with 95% Confidence Intervals (CI) where estimable. Abbreviations: EPIC, The European Prospective Investigation of Cancer; HPFS, Health Professionals Follow-Up Study; NHS, Nurses' Health Study; WHI, Women's Health Initiative.

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

Supplementary Figure 4F. Relationship between substituting water for sugar-sweetened beverages (SSBs) and stroke incidence.

Cohort Comparison		RR [95% CI]	Weight (%)
HPFS & NHS (Bernstein 2012) Overall Test of θ = 0: z = 0.00, p = 1.00	0.80 1.00 1.20 Protective Association Adverse Associati	1.00 [0.94 to 1.06] 1.00 [0.94 to 1.06] - on	100.00

The black diamond represents the pooled summary estimate. Inter-study heterogeneity could not be assessed as only 1 cohort comparison was available for analysis. All results are presented as risk ratio (RR) with 95% Confidence Intervals (CI) where estimable. Abbreviations: HPFS, Health Professionals Follow-Up Study; NHS, Nurses' Health Study.

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

Supplementary Figure 5A. Relationship between substituting low-and no-calorie sweetened beverages (LNCSBs) for water and change in body weight (kg) per year.



The black diamond represents the pooled summary estimate. Inter-study heterogeneity could not be assessed as only 1 cohort comparison was available for analysis. All results are presented as mean difference (MD) per year with 95% Confidence Intervals (CI) where estimable. Abbreviations: SUN, Sequimiento University of Navarra.

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

Supplementary Figure 5B. Relationship between substituting low-and no-calorie sweetened beverages (LNCSBs) for water and obesity (OB) incidence.

Cohort Comparison		RR [95% CI]	Welght (%)
SUN (Fresan 2016) Overall Test of θ = 0: Z = 1.41, p = 0.16	0.50 0.70 1.00 1.50 2.0 Protective Association Adverse Associati	1.19 [0.94 to 1.50] 1.19 [0.94 to 1.50] - no lon	100.00

The black diamond represents the pooled summary estimate. Inter-study heterogeneity could not be assessed as only 1 cohort comparison was available for analysis. All results are presented as risk ratio (RR) with 95% Confidence Intervals (CI) where estimable. Abbreviations: SUN, Sequimiento University of Navarra.

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

Supplementary Figure 5C. Relationship between substituting low-and no-calorie sweetened beverages (LNCSBs) for water and the risk of type 2 diabetes (T2D) using a fixed-effects model.



Fixed-effects inverse-variance model

The black diamond represents the pooled summary estimate. Inter-study heterogeneity was tested using the Cochran Q statistic (χ^2) at a significance level of P_Q<0.10 and quantified by the I² statistic. An I² value \geq 50% was considered to indicate substantial heterogeneity. All results are presented as risk ratio (RR) with 95% Confidence Intervals (CI) where estimable. Abbreviations: HPFS, Health Professionals Follow-Up Study; NHS, Nurses' Health Study; WHI, Women's Health Initiative.

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

Supplementary Figure 5D. Relationship between substituting low-and no-calorie sweetened beverages (LNCSBs) for water and stroke incidence.



The black diamond represents the pooled summary estimate. Inter-study heterogeneity could not be assessed as only 1 cohort comparison was available for analysis. All results are presented as risk ratio (RR) with 95% Confidence Intervals (CI) where estimable. Abbreviations: HPFS, Health Professionals Follow-Up Study; NHS, Nurses' Health Study.

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

Supplementary Figure 6A. Sensitivity analysis of relationship between change in low-and no-calorie sweetened beverage (LNCSB) intake on change in body weight (kg) per year.



Influence analysis: Removal of each cohort comparison, one at a time and recalculation of the overall effect and heterogeneity

Each cohort comparison was systematically removed, and summary estimates were recalculated to assess the influence of each cohort comparison. A cohort comparison was considered influential if it changed the direction, or significance of the pooled estimates or the evidence of heterogeneity. Inter-study heterogeneity was tested using the Cochran Q statistic at a significance level of $P_Q < 0.10$ and quantified by the I² statistic, where I² \geq 50% was considered to indicate substantial heterogeneity. Abbreviations: HPFS, Health Professionals Follow-Up Study; NHS, Nurses' Health Study

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

Supplementary Figure 6B. Sensitivity analysis of relationship between change in low-and no-calorie sweetened beverage (LNCSB) intake on risk of type 2 diabetes (T2D).



Influence analysis: Removal of each cohort study, one at a time and recalculation of the overall effect and heterogeneity

Each cohort comparison was systematically removed, and summary estimates were recalculated to assess the influence of each cohort comparison. A cohort comparison was considered influential if it changed the direction, or significance of the pooled estimates or the evidence of heterogeneity. Inter-study heterogeneity was tested using the Cochran Q statistic at a significance level of $P_Q < 0.10$ and quantified by the I² statistic, where I² \geq 50% was considered to indicate substantial heterogeneity. Abbreviations: HPFS, Health Professionals Follow-Up Study; NHS, Nurses' Health Study.

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

Supplementary Figure 7A. Sensitivity analysis of relationship between substituting low-and nocalorie sweetened beverages (LNCSBs) for sugar-sweetened beverages (SSBs) on change in body weight (kg) per year.



Influence analysis: Removal of each cohort comparison, one at a time and recalculation of the overall effect and heterogeneity

Each cohort comparison was systematically removed, and summary estimates were recalculated to assess the influence of each cohort comparison. A cohort comparison was considered influential if it changed the direction, or significance of the pooled estimates or the evidence of heterogeneity. Inter-study heterogeneity was tested using the Cochran Q statistic at a significance level of $P_Q<0.10$ and quantified by the I² statistic, where I² \geq 50% was considered to indicate substantial heterogeneity. Abbreviations: HPFS, Health Professionals Follow-Up Study; NHS, Nurses' Health Study; SUN, Sequimiento University of Navarra.

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

Supplementary Figure 7B. Sensitivity analysis of relationship between substituting low-and nocalorie sweetened beverages (LNCSBs) for sugar-sweetened beverages (SSBs) and risk of type 2 diabetes (T2D).



Influence analysis: Removal of each cohort study, one at a time and recalculation of the overall effect and heterogeneity

Each cohort comparison was systematically removed, and summary estimates were recalculated to assess the influence of each cohort comparison. A cohort comparison was considered influential if it changed the direction, or significance of the pooled estimates or the evidence of heterogeneity. Inter-study heterogeneity was tested using the Cochran Q statistic at a significance level of $P_Q < 0.10$ and quantified by the I² statistic, where I² \geq 50% was considered to indicate substantial heterogeneity. Abbreviations: EPIC, The European Prospective Investigation of Cancer; HPFS, Health Professionals Follow-Up Study; NHS, Nurses' Health Study; WHI, Women's Health Initiative.

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies





Influence analysis: Removal of each cohort study, one at a time and recalculation of the overall effect and heterogeneity

Each cohort comparison was systematically removed, and summary estimates were recalculated to assess the influence of each cohort comparison. A cohort comparison was considered influential if it changed the direction, or significance of the pooled estimates or the evidence of heterogeneity. Inter-study heterogeneity was tested using the Cochran Q statistic at a significance level of $P_Q<0.10$ and quantified by the I² statistic, where I² \geq 50% was considered to indicate substantial heterogeneity. Abbreviations: ARIC, Atherosclerosis Risk in Communities Study; HPFS, Health Professionals Follow-Up Study; NHS, Nurses' Health Study; WHS: Women's Health Study.

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

Supplementary Figure 7D. Sensitivity analysis of relationship between substituting low-and nocalorie sweetened beverages (LNCSBs) for sugar-sweetened beverages (SSBs) and risk of coronary heart disease (CHD) mortality.



Influence analysis: Removal of each cohort study, one at a time and recalculation of the overall effect and heterogeneity

Each cohort comparison was systematically removed, and summary estimates were recalculated to assess the influence of each cohort comparison. A cohort comparison was considered influential if it changed the direction, or significance of the pooled estimates or the evidence of heterogeneity. Inter-study heterogeneity was tested using the Cochran Q statistic at a significance level of $P_Q < 0.10$ and quantified by the I² statistic, where I² \geq 50% was considered to indicate substantial heterogeneity. Abbreviations: ARIC, Atherosclerosis Risk in Communities Study; HPFS, Health Professionals Follow-Up Study; IWHS, Iowa Women's Health Study; NHS, Nurses' Health Study.

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

Supplementary Figure 8A. Sensitivity analysis of relationship between substituting water for sugarsweetened beverages (SSBs) on change in body weight (kg) per year.



Influence analysis: Removal of each cohort comparison, one at a time and recalculation of the overall effect and heterogeneity

Each cohort comparison was systematically removed, and summary estimates were recalculated to assess the influence of each cohort comparison. A cohort comparison was considered influential if it changed the direction, or significance of the pooled estimates or the evidence of heterogeneity. Inter-study heterogeneity was tested using the Cochran Q statistic at a significance level of $P_Q<0.10$ and quantified by the I² statistic, where I² \geq 50% was considered to indicate substantial heterogeneity. Abbreviations: HPFS, Health Professionals Follow-Up Study; NHS, Nurses' Health Study; SUN, Sequimiento University of Navarra.

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

Supplementary Figure 8B. Sensitivity analysis of relationship between substituting water for sugarsweetened beverages (SSBs) and risk of type 2 diabetes (T2D).

			Risk Ratio			
Cohort Comparison Removed			with 95% CI	PEffect	l² (%)	P _{Heterogeneity}
Overall			0.96 [0.94 to 0.98]	0.001	79	0.009
EPIC Norfolk (O'Connor 2015)			0.97 [0.94 to 0.99]	0.003	87	0.006
HPFS, NHS, NHS II (Drouin-Chartier 2019)			0.90 [0.85 to 0.94]	< 0.001	0	0.765
WHI (Huang 2017)			0.98 [0.95 to 1.00]	0.054	64	0.095
	0.85	1.00	_			

Influence analysis: Removal of each cohort study, one at a time and recalculation of the overall effect and heterogeneity

Each cohort comparison was systematically removed, and summary estimates were recalculated to assess the influence of each cohort comparison. A cohort comparison was considered influential if it changed the direction, or significance of the pooled estimates or the evidence of heterogeneity. Inter-study heterogeneity was tested using the Cochran Q statistic at a significance level of $P_Q < 0.10$ and quantified by the I² statistic, where I² \geq 50% was considered to indicate substantial heterogeneity. Abbreviations: EPIC, The European Prospective Investigation of Cancer; HPFS, Health Professionals Follow-Up Study; NHS, Nurses' Health Study; WHI: Women's Health Initiative.

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

Supplementary Figure 9. Sensitivity analysis of relationship between substituting low-and nocalorie sweetened beverages (LNCSBs) for water and risk of type 2 diabetes (T2D).



Influence analysis: Removal of each cohort study, one at a time and recalculation of the overall effect and heterogeneity

Each cohort comparison was systematically removed, and summary estimates were recalculated to assess the influence of each cohort comparison. A cohort comparison was considered influential if it changed the direction, or significance of the pooled estimates or the evidence of heterogeneity. Inter-study heterogeneity was tested using the Cochran Q statistic at a significance level of $P_Q < 0.10$ and quantified by the I² statistic, where I² \geq 50% was considered to indicate substantial heterogeneity. Abbreviations: HPFS, Health Professionals Follow-Up Study; NHS, Nurses' Health Study; WHI: Women's Health Initiative.

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

Supplementary Figure 10. Linear and non-linear dose-response relation between increasing lowand no-calorie sweetened beverage (LNCSB) intake and risk of type of 2 diabetes (T2D).



Both linear (solid lines) and non-linear (dashed lines along with 95% confidence intervals) dose-response data were modeled using one-stage linear mixed models. For the non-linear model, the relation was allowed to curve by transforming the exposure using restricted cubic splines with three knots. Individual observations are represented by the circles with the size corresponding to their precision. Red dashed line represents risk ratio of 1.0, indicating no change in risk.

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

REFERENCES

1. Mozaffarian D, Hao T, Rimm EB, Willett WC, Hu FB. Changes in diet and lifestyle and long-term weight gain in women and men. N Engl J Med 2011;364:2392-2404

2. Smith JD, Hou T, Hu FB, Rimm EB, Spiegelman D, Willett WC, Mozaffarian D. A Comparison of Different Methods for Evaluating Diet, Physical Activity, and Long-Term Weight Gain in 3 Prospective Cohort Studies. J Nutr 2015;145:2527-2534

3. Ge L, Sadeghirad B, Ball GDC, da Costa BR, Hitchcock CL, Svendrovski A, Kiflen R, Quadri K, Kwon HY, Karamouzian M, Adams-Webber T, Ahmed W, Damanhoury S, Zeraatkar D, Nikolakopoulou A, Tsuyuki RT, Tian J, Yang K, Guyatt GH, Johnston BC. Comparison of dietary macronutrient patterns of 14 popular named dietary programmes for weight and cardiovascular risk factor reduction in adults: systematic review and network meta-analysis of randomised trials. BMJ 2020;369:m696

4. Drouin-Chartier J-P, Zheng Y, Li Y, Malik V, Pan A, Bhupathiraju SN, Tobias DK, Manson JE, Willett WC, Hu FB. Changes in Consumption of Sugary Beverages and Artificially Sweetened Beverages and Subsequent Risk of Type 2 Diabetes: Results From Three Large Prospective US Cohorts of Women and Men. Diabetes Care 2019;42:2181-2189

5. Pan A, Malik VS, Hao T, Willett WC, Mozaffarian D, Hu FB. Changes in water and beverage intake and long-term weight changes: results from three prospective cohort studies. Int J Obes (Lond) 2013;37:1378

6. Stern D, Middaugh N, Rice MS, Laden F, Lopez-Ridaura R, Rosner B, Willett W, Lajous M. Changes in Sugar-Sweetened Soda Consumption, Weight, and Waist Circumference: 2-Year Cohort of Mexican Women. Am J Public Health 2017;107:1801-1808

7. Chen L, Appel LJ, Loria C, Lin PH, Champagne CM, Elmer PJ, Ard JD, Mitchell D, Batch BC, Svetkey LP, Caballero B. Reduction in consumption of sugar-sweetened beverages is associated with weight loss: the PREMIER trial. Am J Clin Nutr 2009;89:1299-1306

8. Stookey JD, Constant F, Popkin BM, Gardner CD. Drinking Water Is Associated With Weight Loss in Overweight Dieting Women Independent of Diet and Activity. Obesity 2008;16:2481-2488

9. Keller A, O'Reilly EJ, Malik V, Buring JE, Andersen I, Steffen L, Robien K, Männistö S, Rimm EB, Willett W. Substitution of sugar-sweetened beverages for other beverages and the risk of developing coronary heart disease: Results from the Harvard Pooling Project of Diet and Coronary Disease. Prev Med 2020;131:105970

10. O'Connor L, Imamura F, Lentjes MA, Khaw KT, Wareham NJ, Forouhi NG. Prospective associations and population impact of sweet beverage intake and type 2 diabetes, and effects of substitutions with alternative beverages. Diabetologia 2015;58:1474-1483

Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

11. Bernstein AM, de Koning L, Flint AJ, Rexrode KM, Willett WC. Soda consumption and the risk of stroke in men and women. Am J Clin Nutr 2012;95:1190-1199

12. Malik VS, Li Y, Pan A, De Koning L, Schernhammer E, Willett WC, Hu FB. Long-Term Consumption of Sugar-Sweetened and Artificially Sweetened Beverages and Risk of Mortality in US Adults. Circulation 2019;139:2113-2125

13. Pan A, Malik VS, Schulze MB, Manson JE, Willett WC, Hu FB. Plain-water intake and risk of type 2 diabetes in young and middle-aged women. Am J Clin Nutr 2012;95:1454-1460

14. Fresan U, Gea A, Bes-Rastrollo M, Ruiz-Canela M, Martinez-Gonzalez MA. Substitution Models of Water for Other Beverages, and the Incidence of Obesity and Weight Gain in the SUN Cohort. Nutrients 2016;8:688

15. Huang M, Quddus A, Stinson L, Shikany JM, Howard BV, Kutob RM, Lu B, Manson JE, Eaton CB. Artificially sweetened beverages, sugar-sweetened beverages, plain water, and incident diabetes mellitus in postmenopausal women: the prospective Women's Health Initiative observational study. Am J Clin Nutr 2017;106:614-622

16. Schwingshackl L, Knüppel S, Schwedhelm C, Hoffmann G, Missbach B, Stelmach-Mardas M, Dietrich S, Eichelmann F, Kontopantelis E, Iqbal K, Aleksandrova K, Lorkowski S, Leitzmann MF, Kroke A, Boeing H. Perspective: NutriGrade: A Scoring System to Assess and Judge the Meta-Evidence of Randomized Controlled Trials and Cohort Studies in Nutrition Research. Adv Nutr 2016;7:994-1004